Olabisi, Opeyemi A. “Has APOL1 kidney disease treatment been hiding in plain sight?” Kidney International 106, no. 6 (December 2024): 1015–17. https://doi.org/10.1016/j.kint.2024.09.003.

Martinelli, Elena, Rik Westland, Opeyemi A. Olabisi, and Simone Sanna-Cherchi. “Prevalence and Impact of APOL1 Kidney Risk Variants in West Africa : Insights for Global Kidney Disease Assessment and Treatment.” Journal of the American Society of Nephrology : JASN, November 2024. https://doi.org/10.1681/asn.0000000587.

Hopper, Timothy, and Opeyemi A. Olabisi. “APOL1 Variant and Kidney Disease-Reply.” JAMA 332, no. 12 (September 24, 2024): 1020–21. https://doi.org/10.1001/jama.2024.14361.

Regan, Jessica A., Michel G. Khouri, Opeyemi A. Olabisi, Kevin M. Alexander, Sadiya S. Khan, Svati H. Shah, and Senthil Selvaraj. “Should We Systematically Screen for the Amyloidogenic V142I Variant?” J Card Fail, September 19, 2024. https://doi.org/10.1016/j.cardfail.2024.08.055.

Nystrom, Sarah E., Karen L. Soldano, Micki Rockett, Somenath Datta, Guojie Li, Daniel Silas, Melanie E. Garrett, Allison E. Ashley-Koch, and Opeyemi A. Olabisi. “APOL1 High-Risk Genotype is Not Associated With New or Worsening of Proteinuria or Kidney Function Decline Following COVID-19 Vaccination.” Kidney Int Rep 9, no. 9 (September 2024): 2657–66. https://doi.org/10.1016/j.ekir.2024.06.023.

Olabisi, Opeyemi A., Nadine J. Barrett, Anika Lucas, Maurice Smith, Kenisha Bethea, Karen Soldano, Stephanie Croall, Azita Sadeghpour, Hrishikesh Chakraborty, and Myles Wolf. “Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE).” Kidney Int Rep 9, no. 9 (September 2024): 2677–84. https://doi.org/10.1016/j.ekir.2024.06.033.

Hopper, Timothy, and Opeyemi A. Olabisi. “APOL1-Mediated Kidney Disease.” JAMA 331, no. 19 (May 21, 2024): 1668–69. https://doi.org/10.1001/jama.2024.2667.

Trachtman, Howard, Hailey Desmond, Amanda L. Williams, Laura H. Mariani, Sean Eddy, Wenjun Ju, Laura Barisoni, et al. “Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today.” Kidney Int 105, no. 2 (February 2024): 218–30. https://doi.org/10.1016/j.kint.2023.11.018.

Datta, Somenath, Brett M. Antonio, Nathan H. Zahler, Jonathan W. Theile, Doug Krafte, Hengtao Zhang, Paul B. Rosenberg, et al. “APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.” J Clin Invest 134, no. 5 (January 16, 2024). https://doi.org/10.1172/JCI172262.

Gipson, Debbie S., Chia-Shi Wang, Eloise Salmon, Rasheed Gbadegesin, Abhijit Naik, Simone Sanna-Cherchi, Alessia Fornoni, et al. “FSGS Recurrence Collaboration: Report of a Symposium.” Glomerular Dis 4, no. 1 (2024): 1–10. https://doi.org/10.1159/000535138.

Hingorani, Sangeeta, Keisha L. Gibson, Yuping Xie, Yujie Wang, Sean Eddy, John Hartman, Matthew Sampson, et al. “The association of low birthweight and prematurity on outcomes in children and adults with nephrotic syndrome-a NEPTUNE cohort study.” Pediatric Nephrology (Berlin, Germany) 38, no. 10 (October 2023): 3297–3308. https://doi.org/10.1007/s00467-023-05876-3.

Olabisi, Opeyemi A. “APOL1 channel blocker reduces proteinuria in FSGS.” Kidney Int 104, no. 2 (August 2023): 228–30. https://doi.org/10.1016/j.kint.2023.04.022.

Mohottige, Dinushika, Opeyemi Olabisi, and L Ebony Boulware. “Use of Race in Kidney Function Estimation: Lessons Learned and the Path Toward Health Justice.” Annu Rev Med 74 (January 27, 2023): 385–400. https://doi.org/10.1146/annurev-med-042921-124419.

Olabisi, Opeyemi A., Susanne B. Nicholas, and Keith C. Norris. “Race, Ancestry, and Genetic Risk for Kidney Failure.” Am J Kidney Dis 80, no. 6 (December 2022): 801–4. https://doi.org/10.1053/j.ajkd.2022.08.008.

Wester, C William, Bryan E. Shepherd, Usman J. Wudil, Baba Maiyaki Musa, Donna J. Ingles, Heather L. Prigmore, Faisal S. Dankishiya, et al. “Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design.” BMC Infect Dis 22, no. 1 (July 4, 2022): 591. https://doi.org/10.1186/s12879-022-07531-y.

Nystrom, Sarah E., Guojie Li, Somenath Datta, Karen L. Soldano, Daniel Silas, Astrid Weins, Gentzon Hall, David B. Thomas, and Opeyemi A. Olabisi. “JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.” JCI Insight 7, no. 11 (June 8, 2022). https://doi.org/10.1172/jci.insight.157432.

National Kidney Foundation Research Roundtable Work Group on behalf of the National Kidney Foundation. “Research Priorities for Kidney-Related Research-An Agenda to Advance Kidney Care: A Position Statement From the National Kidney Foundation.” Am J Kidney Dis 79, no. 2 (February 2022): 141–52. https://doi.org/10.1053/j.ajkd.2021.08.018.

Wu, Dongling, Opeyemi Olabisi, Zachary Kozel, Oksana Yaskiv, Yihe Yang, and Vanesa Bijol. “ApoL1 Genotype in African American Patients with Kidney Neoplasm.” In MODERN PATHOLOGY, 35:695–97, 2022.

Wu, Dongling, Opeyemi Olabisi, Zachary Kozel, Oksana Yaskiv, Yihe Yang, and Vanesa Bijol. “ApoL1 Genotype in African American Patients with Kidney Neoplasm.” In LABORATORY INVESTIGATION, 102:695–97, 2022.

DeOliveira, Margaret, Colby Feeney, Caroline Leahy, Sarah Nystrom, David N. Howell, Samira S. Farouk, Ming Wu, Opeyemi A. Olabisi, and Matthew A. Sparks. “Collapsing Glomerulopathy in Identical Twins With Lupus and High-Risk Apolipoprotein L1 (APOL1) Genotype.” Kidney Int Rep 6, no. 9 (September 2021): 2501–4. https://doi.org/10.1016/j.ekir.2021.06.005.

Olabisi, Opeyemi A., and Barry I. Freedman. “APOL1-associated kidney disease in northern Nigerians with treated HIV infection.” Kidney Int 100, no. 1 (July 2021): 19–21. https://doi.org/10.1016/j.kint.2021.04.023.

Freedman, Barry I., Wylie Burke, Jasmin Divers, Lucy Eberhard, Crystal A. Gadegbeku, Rasheed Gbadegesin, Michael E. Hall, et al. “Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.” J Am Soc Nephrol 32, no. 7 (July 2021): 1765–78. https://doi.org/10.1681/ASN.2020101399.

Datta, Somenath, Rama Kataria, Jia-Yue Zhang, Savannah Moore, Kaitlyn Petitpas, Adam Mohamed, Nathan Zahler, Martin R. Pollak, and Opeyemi A. Olabisi. “Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.” J Am Soc Nephrol 31, no. 9 (September 2020): 2083–96. https://doi.org/10.1681/ASN.2020010079.

Norris, Keith C., Opeyemi Olabisi, M Edwina Barnett, Yuan-Xiang Meng, David Martins, Chamberlain Obialo, Jae Eun Lee, and Susanne B. Nicholas. “The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease.” Int J Environ Res Public Health 15, no. 12 (November 30, 2018). https://doi.org/10.3390/ijerph15122701.

Olabisi, Opeyemi A., and John F. Heneghan. “APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?” Semin Nephrol 37, no. 6 (November 2017): 546–51. https://doi.org/10.1016/j.semnephrol.2017.07.008.

Olabisi, Opeyemi A., Jia-Yue Zhang, Lynn VerPlank, Nathan Zahler, Salvatore DiBartolo, John F. Heneghan, Johannes S. Schlöndorff, et al. “APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.” Proc Natl Acad Sci U S A 113, no. 4 (January 26, 2016): 830–37. https://doi.org/10.1073/pnas.1522913113.

Olabisi, O., and J. V. Bonventre. “Acute kidney injury in cancer patients.” In Onconephrology: Cancer, Chemotherapy and the Kidney, 1–24, 2015. https://doi.org/10.1007/978-1-4939-2659-6_1.

Suk, Hee Yun, Chen Zhou, Teddy T. C. Yang, Hong Zhu, Raymond Y. L. Yu, Opeyemi Olabisi, XiaoYong Yang, et al. “Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.” J Biol Chem 288, no. 5 (February 1, 2013): 3477–88. https://doi.org/10.1074/jbc.M112.419150.

Olabisi, Opeyemi A., and Chi-Wing Chow. “Assay for protein modification by poly-ADP-ribose in vitro.” Methods Mol Biol 780 (2011): 47–55. https://doi.org/10.1007/978-1-61779-270-0_3.

Zhu, Hong, Hee Yun Suk, Raymond Y. L. Yu, Deborah Brancho, Opeyemi Olabisi, Teddy T. C. Yang, XiaoYong Yang, et al. “Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.” Mol Cell Biol 30, no. 18 (September 2010): 4379–90. https://doi.org/10.1128/MCB.01193-09.

Olabisi, Opeyemi A., Noemi Soto-Nieves, Edward Nieves, Teddy T. C. Yang, Xiaoyong Yang, Raymond Y. L. Yu, Hee Yun Suk, Fernando Macian, and Chi-Wing Chow. “Regulation of transcription factor NFAT by ADP-ribosylation.” Mol Cell Biol 28, no. 9 (May 2008): 2860–71. https://doi.org/10.1128/MCB.01746-07.

Yang, Teddy T. C., Hee Yun Suk, Xiaoyong Yang, Opeyemi Olabisi, Raymond Y. L. Yu, Jorge Durand, Linda A. Jelicks, et al. “Role of transcription factor NFAT in glucose and insulin homeostasis.” Mol Cell Biol 26, no. 20 (October 2006): 7372–87. https://doi.org/10.1128/MCB.00580-06.

Broderick, Patricia A., Opeyemi A. Olabisi, David N. Rahni, and Yueping Zhou. “Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.” Prog Neuropsychopharmacol Biol Psychiatry 28, no. 3 (May 2004): 547–57. https://doi.org/10.1016/j.pnpbp.2004.01.007.

Olabisi, Opeyemi, Khaldoun Al-Romaih, Joel Henderson, Ritu Tomar, Iain Drummond, Calum MacRae, and Martin Pollak. “From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?” Clin Nephrol 86 (2016), no. 13 (n.d.): 114–18. https://doi.org/10.5414/CNP86S116.